Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.

Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC.

Am J Obstet Gynecol. 2008 Apr;198(4):418.e1-7. doi: 10.1016/j.ajog.2007.10.792. Epub 2008 Feb 1.

PMID:
18241816
2.

Plasma calprotectin concentrations in women with endometrial carcinoma.

Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC.

Gynecol Oncol. 2009 Sep;114(3):491-5. doi: 10.1016/j.ygyno.2009.06.008. Epub 2009 Jul 3.

PMID:
19577278
3.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
4.

LyGDI is a promising biomarker for ovarian cancer.

Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L, Zhang X.

Int J Gynecol Cancer. 2010 Apr;20(3):316-22. doi: 10.1111/IGC.0b013e3181d0b02d.

PMID:
20375790
5.

Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC.

Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105. doi: 10.1016/j.ejogrb.2008.08.011. Epub 2008 Nov 7. Review.

PMID:
18995946
6.

Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C, Dieplinger B, Hubalek M, Wilkinson N, Perren TJ, Kehoe S, Hall GD, Daxenbichler G, Dieplinger H, Selby PJ, Banks RE.

Clin Cancer Res. 2007 Dec 15;13(24):7370-9.

7.

Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.

Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H, Stieber P.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1127-33. doi: 10.1158/1055-9965.EPI-08-0653. Epub 2009 Mar 31.

8.

Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.

Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D.

J BUON. 2007 Jan-Mar;12(1):99-104.

PMID:
17436409
9.

Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.

Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.

Gynecol Oncol. 2006 Sep;102(3):542-5. Epub 2006 Feb 28.

PMID:
16510173
10.

Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.

Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.

Gynecol Oncol. 2005 Feb;96(2):516-9.

PMID:
15661245
11.

Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary.

Ødegaard E, Davidson B, Engh V, Onsrud M, Staff AC.

Am J Obstet Gynecol. 2008 Nov;199(5):533.e1-8. doi: 10.1016/j.ajog.2008.04.004. Epub 2008 Jun 4.

PMID:
18533117
12.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

13.

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.

Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A.

Int J Gynecol Cancer. 2009 Aug;19(6):1015-21. doi: 10.1111/IGC.0b013e3181ab597f.

PMID:
19820362
14.

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.

van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF.

Cancer. 2001 Dec 1;92(11):2837-44.

PMID:
11753957
15.

Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma.

Ahmed N, Oliva K, Rice GE, Quinn MA.

Clin Cancer Res. 2004 Apr 1;10(7):2415-20.

16.

[Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].

Dong L, Cui H, Li XP, Sun LF, Chang XH, Liang XD, Zhu HL.

Zhonghua Fu Chan Ke Za Zhi. 2008 Jan;43(1):5-8. Chinese.

PMID:
18366923
17.

[The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].

ławicki S, Czygier M, Gacuta-Szumarska E, Knapp P, Szmitkowski M.

Pol Merkur Lekarski. 2006 Nov;21(125):465-8. Polish.

PMID:
17345841
18.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
20.

Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.

Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K.

Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):67-70. Epub 2005 Dec 15.

PMID:
16359773

Supplemental Content

Support Center